Teenager Suffered from Idiopathic Anaphylaxis and Chronic Spontaneous Urticaria Successfully Treated with Omalizumab: A Case Report

被引:4
作者
Olszowiec-Chlebna, Malgorzata [1 ]
Sztafinska, Anna [1 ]
Stelmach, Iwona [1 ]
机构
[1] Med Univ Lodz, N Copernicus Hosp, Dept Pediat & Allergy, 62 Pabianicka Str, PL-93513 Lodz, Poland
关键词
SOLAR URTICARIA; MANAGEMENT;
D O I
10.1089/ped.2015.0580
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Anaphylaxis is a serious and probably lethal systemic reaction. When a trigger cannot be determined, idiopathic anaphylaxis is considered. It can occur as a complication of chronic spontaneous urticaria (CSU). In idiopathic anaphylaxis presenting with frequent attacks, long-term prophylaxis with H1antihistamines and steroid treatment is recommended but rarely effective. Omalizumab, a humanized monoclonal antibody drug that decreases free immunoglobulin E molecules in the circulation, is approved for the treatment of chronic severe persistent allergic asthma and CSU. We report a 15-year-old female patient suffering from CSU concomitant with idiopathic anaphylaxis. Omalizumab at a dose of 300 mg once every 4 weeks was administered for 6 months. The patient has remained asymptomatic during therapy and 3 months after the end of the therapy.
引用
收藏
页码:53 / 55
页数:3
相关论文
共 13 条
  • [1] Treatment with omalizumab in a 16-year-old Caucasian girl with refractory solar urticaria
    Arasi, Stefania
    Crisafulli, Giuseppe
    Caminiti, Lucia
    Guarneri, Fabrizio
    Aversa, Tommaso
    Porcaro, Federica
    Pajno, Giovanni B.
    [J]. PEDIATRIC ALLERGY AND IMMUNOLOGY, 2015, 26 (06) : 583 - 585
  • [2] Chronic idiopathic urticaria and anxiety symptoms
    Barbosa, Filipe
    Freitas, Joao
    Barbosa, Antonio
    [J]. JOURNAL OF HEALTH PSYCHOLOGY, 2011, 16 (07) : 1038 - 1047
  • [3] Promising option in the prevention of idiopathic anaphylaxis: Omalizumab
    Demirturk, Mustafa
    Gelincik, Asli
    Colakoglu, Bahattin
    Dal, Murat
    Buyukozturk, Suna
    [J]. JOURNAL OF DERMATOLOGY, 2012, 39 (06) : 552 - 554
  • [5] Successful omalizumab treatment of severe solar urticaria in a 6-year-old child
    Levi, A.
    Tal, Y.
    Dranitzki, Z.
    Shalit, M.
    Enk, C. D.
    [J]. PEDIATRIC ALLERGY AND IMMUNOLOGY, 2015, 26 (06) : 588 - 590
  • [6] Naaman Sandra, 2014, Skin Therapy Lett, V19, P1
  • [7] Management of pediatric chronic spontaneous and physical urticaria patients with omalizumab: case series
    Netchiporouk, Elena
    Nguyen, Christopher H.
    Thuraisingham, Thusanth
    Jafarian, Fatemeh
    Maurer, Marcus
    Ben-Shoshan, Moshe
    [J]. PEDIATRIC ALLERGY AND IMMUNOLOGY, 2015, 26 (06) : 585 - 588
  • [8] Successful treatment of idiopathic anaphylaxis in an adolescent
    Pitt, Tracy J.
    Cisneros, Nestor
    Kalicinsky, Chrystyna
    Becker, Allan B.
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2010, 126 (02) : 415 - 416
  • [9] A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria
    Saini, Sarbjit
    Rosen, Karin E.
    Hsieh, Hsin-Ju
    Wong, Dennis A.
    Conner, Edward
    Kaplan, Allen
    Spector, Sheldon
    Maurer, Marcus
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2011, 128 (03) : 567 - U195
  • [10] Development of a monoclonal anti-immunoglobulin E antibody (omalizumab) for the treatment of allergic respiratory disorders
    Schulman, ES
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2001, 164 (08) : S6 - S11